Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.

@article{Li2009EffectsOT,
  title={Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.},
  author={Zhi Li and Guo-Cai Wang and L Wang and Wei Zhang and Z R Tan and Lan Fan and B-l Chen and Qian Li and Jie Liu and J-H Tu and D Hu and Z Liu and H Zhou},
  journal={Xenobiotica; the fate of foreign compounds in biological systems},
  year={2009},
  volume={39 10},
  pages={788-93}
}
The aim of the study was to determine the pharmacokinetics of losartan in relation to the CYP2C9*13 allele. A single oral dose of 50 mg losartan was administrated to each of the 16 healthy male volunteers with a different genotype (CYP2C9*1/*1, n = 6; CYP2C9*1/*13, n = 4; and CYP2C9*1/*3, n = 6). Blood samples were collected from pre-dose up to 24 h after the drug administration. Plasma losartan and E3174 (an active metabolite of losartan) were assayed by liquid chromatography-tandem mass… CONTINUE READING

From This Paper

Topics from this paper.
7 Citations
0 References
Similar Papers